| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
iBio Inc. (NASDAQ:IBIO) is trading up 11.51% to $1.55 in Thursday’s pre-market session.
Check out the current price of IBIO stock here.
IBIO closed Wednesday's regular session at $1.39, up 25.23%, according to Benzinga Pro data.
The San Diego-based biotech announced on Tuesday that its executives will present data on its obesity treatment candidate, IBIO-610, at two industry conferences in November.
Dr. Cory Schwartz, Director of Research and Early Development at iBio, is scheduled to present on November 4 at 2 p.m. EST in Atlanta.
His presentation, titled "Discovery and Testing of a First-in-Class Activin E Antagonist Antibody for the Treatment of Obesity," will include data from nonhuman primate studies.
See Also: What's Driving Beyond Meat's 11% After-Hours Drop?
Martin Brenner, CEO and chief scientific officer of the AI-driven biotech, will present on Nov. 12 at 11:45 a.m. WET in Lisbon on "A First-in-Class Anti-Activin E Antibody Induces Fat-Selective Weight Loss in Diet-Induced Obese Mice."
“These findings add to a growing body of research that inhibiting Activin E signaling could deliver fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies,” Brenner stated in the announcement.
The stock is down 43.27% year-to-date but has gained 82.89% over the past six months.
iBio Inc. has a 52-week range of $0.56 to $6.89, with a market capitalization of $28.15 million and an average daily trading volume of 2.64 million shares.
Benzinga’s Edge Stock Rankings indicate that IBIO is experiencing long-term consolidation. Know how its momentum lines up with other well-known names.
Read Next:
Photo Courtesy: Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Posted In: IBIO
